Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses
Table 1
Clinicopathologic characteristics of breast cancer patients in recurrence status.
Variable
No recurrence ()
Recurrence ()
P
%
%
MRE11 positive cells
0.030
≤50%
73
33.18
5
14.71
>50%
147
66.82
29
85.29
Stage
<0.001
I
88
40.00
2
5.88
II, III
132
60.00
32
94.12
Grade
0.543
1, 2
166
75.45
24
70.59
3
54
24.55
10
29.41
Age
0.007
<52 yrs
126
57.27
11
32.35
≥52 yrs
94
42.73
23
67.65
BMI (kg/m2)
0.151
<24
126
57.27
15
44.12
≥24
94
42.73
19
55.88
Tumor size (cm)
<0.001
<2.4 cm
150
68.18
11
32.35
≥2.4 cm
70
31.82
23
67.65
LN metastasis
0.003
Negative
149
67.73
14
41.18
Positive
71
32.27
20
58.82
ER
<0.001
Negative
63
28.64
20
58.82
Positive
157
71.36
14
41.18
PR
0.009
Negative
90
40.91
22
64.71
Positive
130
59.09
12
35.29
HER2 status
0.430
Negative
140
63.64
24
70.59
Positive
80
36.36
10
29.41
Triple negative
0.002
No
190
86.36
22
64.71
Yes
30
13.64
12
35.29
RT
0.021
No
91
41.36
7
20.59
Yes
129
58.64
27
79.41
CT
0.866
No
30
13.64
5
14.71
Yes
190
86.36
29
85.29
HT
0.001
No
72
32.73
21
61.76
Yes
148
67.27
13
38.24
Dataset was retrieved from our previous study [9]. MRE11: meiotic recombination 11; BMI: body mass index; LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; RT: radiotherapy; CT: chemotherapy; HT: hormone therapy.
